AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial

AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial

Source: 
Fierce Pharma
snippet: 

AstraZeneca felt the blow last month when Mystic, a key trial examining its immuno-oncology drug Imfinzi in previously untreated lung cancer, failed. But now that the dust has settled, the company is looking for bright spots in the miss.